Sample size considerations for superiority trials in systemic lupus erythematosus (SLE)

Area of Science:

• Clinical Trials
• Biostatistics
• Rheumatology

Background:

• Sample size calculations are essential for efficient and ethical clinical trial design.
• Traditional methods often rely on statistical power for hypothesis testing.
• Accurate estimation of treatment effects is paramount in clinical research.

Purpose of the Study:

• To highlight statistical issues in sample size estimation for Systemic Lupus Erythematosus (SLE) superiority trials.
• To advocate for confidence interval (CI) width-based sample size methods.
• To provide practical guidance for designing better clinical trials.

Main Methods:

• Discusses statistical power for hypothesis testing in sample size calculations.
• Explains the advantages of using confidence intervals (CIs) over P-values for reporting trial results.
• Presents methods and examples for sample size calculations based on CI width for various outcome types.

Main Results:

• Sample size methods should align with the intended data analysis, favoring CI width for precise parameter estimation.
• CI-based methods ensure that trials are designed to accurately estimate clinically relevant differences.
• Hypothesis testing-based methods may be less optimal for ensuring precise outcome estimation.

Conclusions:

• Confidence interval width methods are preferred for sample size calculations in clinical trials, particularly for SLE.
• Better designed trials, informed by appropriate sample size methods and statistical consultation, lead to more accurate estimation of treatment outcomes.
• This approach ultimately advances the treatment of patients with SLE.